Leerink Partnrs Has Positive Outlook for TNYA Q2 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Research analysts at Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for Tenaya Therapeutics in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($0.16) per share for the quarter, up from their previous forecast of ($0.17). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.66) EPS.

A number of other equities research analysts have also recently commented on TNYA. Morgan Stanley reduced their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, March 12th. Canaccord Genuity Group reduced their price objective on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, April 25th. Finally, Chardan Capital reissued a “buy” rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a report on Friday, May 9th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $6.25.

Tenaya Therapeutics Price Performance

Shares of NASDAQ:TNYA opened at $0.39 on Monday. Tenaya Therapeutics has a 1-year low of $0.36 and a 1-year high of $4.78. The stock has a market cap of $34.54 million, a P/E ratio of -0.27 and a beta of 2.99. The firm has a fifty day moving average price of $0.53 and a 200 day moving average price of $1.35.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Wednesday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06).

Insider Activity at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the stock in a transaction dated Wednesday, March 5th. The shares were acquired at an average cost of $0.70 per share, with a total value of $24,999,998.80. Following the purchase, the insider now directly owns 49,313,559 shares in the company, valued at $34,519,491.30. This trade represents a 262.62% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 19,621 shares of company stock worth $10,595 over the last 90 days. Company insiders own 32.76% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TNYA. JPMorgan Chase & Co. raised its holdings in Tenaya Therapeutics by 20,670.3% during the fourth quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company’s stock worth $7,373,000 after purchasing an additional 5,130,774 shares during the last quarter. Trustees of Columbia University in the City of New York purchased a new position in shares of Tenaya Therapeutics in the fourth quarter valued at $417,000. Nuveen LLC acquired a new position in shares of Tenaya Therapeutics during the 1st quarter worth $129,000. Virtu Financial LLC acquired a new position in shares of Tenaya Therapeutics during the 4th quarter worth $150,000. Finally, Deutsche Bank AG boosted its position in shares of Tenaya Therapeutics by 304.1% in the 4th quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock worth $185,000 after buying an additional 97,318 shares in the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.